High-dose chemotherapy in breast cancer: Dutch randomized studies

Por Rodenhuis, S, van Tinteren, H, de Vries, EGE
Publicado em 2001

Adjuvant treatment in colorectal cancer

Por Taal, B G, van Tinteren, H, van t Veer, L
Publicado em 2002

Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III

Por Taal, B G, Van Tinteren, H, Zoetmulder, F A N
Publicado em 2001

First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis

Por Holleman MS, van Tinteren H, Groen HJM, Al MJ, Uyl-de Groot CA
Publicado em 2019-02-01

A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer.

Por Michalides, R., Hageman, P., van Tinteren, H., Houben, L., Wientjens, E., Klompmaker, R., Peterse, J.
Publicado em 1996

Prospective use of serial questionnaires to evaluate the therapeutic efficacy of (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in suspected lung cancer

Por Herder, G, van Tinteren, H, Comans, E, Hoekstra, O, Teule, G, Postmus, P, Joshi, U, Smit, E
Publicado em 2003

Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment

Por Michalides, R, van Tinteren, H, Balkenende, A, Vermorken, J B, Benraadt, J, Huldij, J, van Diest, P
Publicado em 2002

Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option

Por Meulendijks, D, Dewit, L, Tomasoa, N B, van Tinteren, H, Beijnen, J H, Schellens, J H M, Cats, A
Publicado no Br J Cancer (2014)

Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology.

Por Huijgens, P C, Simoons-Smit, A M, van Loenen, A C, Prooy, E, van Tinteren, H, Ossenkoppele, G J, Jonkhoff, A R
Publicado em 1999

Concurrent chemotherapy (carboplatin, paclitaxel, etoposide) and involved-field radiotherapy in limited stage small cell lung cancer: a Dutch multicenter phase II study

Por Baas, P, Belderbos, J S A, Senan, S, Kwa, H B, van Bochove, A, van Tinteren, H, Burgers, J A, van Meerbeeck, J P
Publicado em 2006

Effects of interleukin-3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumours.

Por Dercksen, M. W., Hoekman, K., ten Bokkel Huinink, W. W., Rankin, E. M., Dubbelman, R., van Tinteren, H., Wagstaff, J., Pinedo, H. M.
Publicado em 1993

Long-term impact of the 70-gene signature on breast cancer outcome

Por Drukker, C. A., van Tinteren, H., Schmidt, M. K., Rutgers, E. J. Th., Bernards, R., van de Vijver, M. J., van’t Veer, L. J.
Publicado em 2014

Soluble epidermal growth factor receptor (sEGFR) and carcinoembryonic antigen (CEA) concentration in patients with non-small cell lung cancer: correlation with survival after erlot...

Por Kappers, I, Vollebergh, M A, van Tinteren, H, Korse, C M, Nieuwenhuis, L L, Bonfrer, J M G, Klomp, H M, van Zandwijk, N, van den Heuvel, M M
Publicado em 2010

The Breast Imaging Reporting and Data System (BI-RADS) in the Dutch breast cancer screening programme: its role as an assessment and stratification tool

Por Timmers, J. M. H., van Doorne-Nagtegaal, H. J., Zonderland, H. M., van Tinteren, H., Visser, O., Verbeek, A. L. M., den Heeten, G. J., Broeders, M. J. M.
Publicado em 2012

Differential prognostic impact of hypoxia induced and diffuse HIF-1α expression in invasive breast cancer

Por Vleugel, M M, Greijer, A E, Shvarts, A, van der Groep, P, van Berkel, M, Aarbodem, Y, van Tinteren, H, Harris, A L, van Diest, P J, van der Wall, E
Publicado em 2005

A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study

Por Drukker, CA, Bueno-de-Mesquita, JM, Retèl, VP, van Harten, WH, van Tinteren, H, Wesseling, J, Roumen, RMH, Knauer, M, van 't Veer, LJ, Sonke, GS, Rutgers, EJT, van de Vijver, MJ, Linn, SC
Publicado em 2013

Treatment and outcome of patients with relapsed clear cell sarcoma of the kidney: a combined SIOP and AIEOP study

Por Gooskens, S L, Furtwängler, R, Spreafico, F, van Tinteren, H, de Kraker, J, Vujanic, G M, Leuschner, I, Coulomb-L'Herminé, A, Godzinski, J, Schleiermacher, G, Stoneham, S, Bergeron, C, Pritchard-Jones, K, Graf, N, van den Heuvel-Eibrink, M M
Publicado em 2014

Molecular subtypes of breast cancer and amplification of topoisomerase IIα: predictive role in dose intensive adjuvant chemotherapy

Por Hannemann, J, Kristel, P, van Tinteren, H, Bontenbal, M, van Hoesel, Q G C M, Smit, W M, Nooij, M A, Voest, E E, van der Wall, E, Hupperets, P, de Vries, E G E, Rodenhuis, S, van de Vijver, M J
Publicado em 2006

A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of th...

Por Smorenburg, C. H., de Groot, S. M., van Leeuwen-Stok, A. E., Hamaker, M. E., Wymenga, A. N., de Graaf, H., de Jongh, F. E., Braun, J. J., Los, M., Maartense, E., van Tinteren, H., Nortier, J. W. R., Seynaeve, C.
Publicado no Ann Oncol (2014)

Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms

Por Drukker, C. A., Nijenhuis, M. V., Bueno-de-Mesquita, J. M., Retèl, V. P., van Harten, W. H., van Tinteren, H., Wesseling, J., Schmidt, M. K., van’t Veer, L. J., Sonke, G. S., Rutgers, E. J. T., van de Vijver, M. J., Linn, S. C.
Publicado em 2014